HEMLIBRA is a treatment for people with hemophilia A with or without factor VIII inhibitors

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

  • Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.
  • HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.
  • HEMLIBRA can reduce all bleeds (whether treated or not), and the number of treated bleeding episodes, including joint bleeds, spontaneous bleeds, and target joint bleeds.

HEMLIBRA is not a cure for hemophilia.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

How HEMLIBRA is thought to work

HEMLIBRA is thought to bridge activated factor IX (9) and factor X (10) to restore the function of missing activated factor VIII (8) to help your blood clot.

FIXa=activated factor IX (9); FX=factor X (10).

HEMLIBRA offers steady and consistent levels between doses, so there's no need to adjust dosing based on activities

HEMLIBRA has a half-life of 4 weeks* 

Treatment will begin with a loading dose once weekly for 4 weeks to increase the levels of HEMLIBRA in your blood. When the loading dose is complete, you will take a maintenance dose, which helps HEMLIBRA levels in your blood remain steady. Your healthcare provider will decide how often you should take your maintenance dose, which can be once weekly, once every 2 weeks, or once every 4 weeks. 

Lower levels of HEMLIBRA in blood were expected in children less than 6 months old.

*After multiple subcutaneous injections, the amount of time estimated for the body to clear half of HEMLIBRA from the blood is 4 weeks.

Sign Up for Our National Webcast

Learn more about HEMLIBRA for people without factor VIII inhibitors

Connects Patient Resource Center

Get support and resources from HEMLIBRA

Find Your Clinical Educator

Get connected with your local Clinical Educator